Page last updated: 2024-11-05

thalidomide and Feuerstein-Mims Syndrome

thalidomide has been researched along with Feuerstein-Mims Syndrome in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ossorio-García, L1
Jiménez-Gallo, D1
Collantes-Rodríguez, C1
Báez-Perea, JM1
Linares-Barrios, M1

Other Studies

1 other study available for thalidomide and Feuerstein-Mims Syndrome

ArticleYear
Treatment of inflammatory linear verrucous epidermal nevus pruritus with thalidomide.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:9

    Topics: Adult; Antipruritics; Humans; Male; Nevus, Sebaceous of Jadassohn; Pruritus; Skin Neoplasms; Thalido

2018